ArriVent BioPharma (AVBP) Financials

ArriVent BioPharma remains a development-stage company with no reported revenue in the periods provided. In Q2 2026, the company recorded a net loss of $49.9 million, compared with losses of $43.3 million in Q1 2026 and $31.4 million in Q2 2025. The widening loss reflects higher operating costs, particularly research and development spending, which increased to $42.3 million from $37.6 million in Q1 2026 and $27.7 million in Q2 2025.

Cash flow remains heavily dependent on financing. ArriVent used $39.6 million in operating cash during Q2 2026, an improvement from the $41.9 million used in Q1 but considerably above the $26.1 million used in Q2 2025. The company raised $85.2 million through common-stock issuance in Q2 2026, following $54.7 million in Q1. This helped drive a $92.6 million increase in cash and equivalents during the quarter, although the increase was primarily financing-driven rather than generated by operations.

The balance sheet provides a substantial liquidity cushion but also highlights continued dilution and accumulated losses. Cash and short-term investments totaled $373.1 million at June 30, 2026, up from $326.3 million at March 31 and $235.7 million a year earlier. However, basic weighted-average shares outstanding rose to 47.6 million in Q2 2026 from 35.0 million in Q2 2025. At the Q2 operating burn rate, the company’s cash and short-term investments represent roughly nine quarters of coverage before considering changes in spending, clinical milestones, or additional financing.

• Liquidity improved: Cash and short-term investments increased to $373.1 million in Q2 2026, compared with $235.7 million in Q2 2025.
• Debt remains minimal: Total liabilities were only $27.9 million at June 30, 2026, including just $33,000 of noncurrent liabilities.
• Operating cash burn eased sequentially: Cash used in operations declined to $39.6 million in Q2 2026 from $41.9 million in Q1 2026.
• Investment income provides some support: Interest and investment income contributed $2.8 million in Q2 2026, partially offsetting operating expenses.
• Investment activity is mainly portfolio management: Q2 investing cash flow was positive $46.1 million because $60.1 million of investments were sold or matured, while $14.0 million were purchased; this is not recurring operating revenue.
• Equity-funded balance-sheet growth: Total assets increased to $394.7 million from $269.5 million in Q2 2025, but much of the improvement was supported by common-stock issuance rather than earnings.
• No revenue was reported: Total revenue and gross profit were both zero in Q2 2026 and throughout the income-statement periods supplied.
• Net losses are expanding: The Q2 2026 loss of $49.9 million was larger than the $43.3 million loss in Q1 2026 and the $31.4 million loss in Q2 2025.
• Research spending is accelerating: Q2 2026 research and development expense rose approximately 53% year over year to $42.3 million, while selling, general and administrative expense increased about 75% to $10.4 million.
• Shareholder dilution is significant: Basic weighted-average shares outstanding increased to 47.6 million in Q2 2026 from 35.0 million in Q2 2025, reflecting the company’s reliance on equity financing.